Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy | Zendy

Salim S. Abdool Karim | Zendy; Kogieleum Naidoo | Zendy; Anneke Grobler | Zendy; Nesri Padayatchi | Zendy; Cheryl Baxter | Zendy; Andy Gray | Zendy; Tanuja N. Gengiah | Zendy; Gonasagrie Nair | Zendy; Sheila Bamber | Zendy; Aarthi Singh | Zendy; Munira Khan | Zendy; Jacqueline Pienaar | Zendy; Wafaa ElSadr | Zendy; Gerald Friedland | Zendy; Quarraisha Abdool Karim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy

Author(s) -

Salim S. Abdool Karim,

Kogieleum Naidoo,

Anneke Grobler,

Nesri Padayatchi,

Cheryl Baxter,

Andy Gray,

Tanuja N. Gengiah,

Gonasagrie Nair,

Sheila Bamber,

Aarthi Singh,

Munira Khan,

Jacqueline Pienaar,

Wafaa ElSadr,

Gerald Friedland,

Quarraisha Abdool Karim

Publication year - 2010

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0905848

Subject(s) - medicine , tuberculosis , efavirenz , didanosine , lamivudine , regimen , coinfection , hazard ratio , mortality rate , surgery , confidence interval , antiretroviral therapy , immunology , viral load , human immunodeficiency virus (hiv) , virus , pathology , hepatitis b virus

The rates of death are high among patients with coinfection with tuberculosis and the human immunodeficiency virus (HIV). The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis therapy remains controversial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research